LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) – Synta today announced the publication in Molecular Cancer Therapeutics of ganetespib results including pharmacologic and biological properties that distinguish ganetespib from other Hsp90 inhibitors.
